Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Intensifies Search For Drugs With A New Development Center In Mumbai

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - From forging alliances for drug discovery research in India, Johnson & Johnson has taken one step forward and established in what it called "the first of its kind" late-phase new chemical entity Analytical and Pharmaceutical Development Center at its North Mumbai facility

You may also be interested in...



J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News

For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.

J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News

For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.

MNCs Increasingly Investing In Diseases Affecting Developing Countries – IFPMA

HONG KONG - Underscoring what may be a subtle but ongoing change in focus for the industry, pharmaceutical companies appear to be increasingly focused on chronic diseases, child and maternal health and other issues of developing countries

Related Content

UsernamePublicRestriction

Register

ID1124690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel